NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care, today announced the closing of its previously announced
Will Trade on the Nasdaq Global Market Under Ticker “GBS” NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of
Will Trade on the Nasdaq Global Market Under Ticker “GBS” NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of
The iQ Group Global has announced a collaboration with Harvard University to develop a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time. Life Science Biosensor Diagnostics Pty Ltd (LSBD), a development company of The iQ Group Global,
The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) has commenced engagement with the US Food and Drug Administration (FDA) for the approval pathway of the Saliva Glucose Biosensor. On May 1 st , LSBD lodged a 513(g) submission, the first step to
The world’s first non-invasive, saliva-based glucose test for diabetes management SYDNEY – February , 2019 – The iQ Group Global, a consortium of life science and financial services companies which span the biopharma value chain from asset discovery to commercialization, today introduced the Saliva
